356 related articles for article (PubMed ID: 27809841)
1. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
2. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
Chinni SR; Yamamoto H; Dong Z; Sabbota A; Bonfil RD; Cher ML
Mol Cancer Res; 2008 Mar; 6(3):446-57. PubMed ID: 18337451
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
4. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
Chinni SR; Sivalogan S; Dong Z; Filho JC; Deng X; Bonfil RD; Cher ML
Prostate; 2006 Jan; 66(1):32-48. PubMed ID: 16114056
[TBL] [Abstract][Full Text] [Related]
5. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
7. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration.
Zieger-Naumann K; Kuhl F; Engele J
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418
[TBL] [Abstract][Full Text] [Related]
8. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model.
Shanmugam MK; Manu KA; Ong TH; Ramachandran L; Surana R; Bist P; Lim LH; Kumar AP; Hui KM; Sethi G
Int J Cancer; 2011 Oct; 129(7):1552-63. PubMed ID: 21480220
[TBL] [Abstract][Full Text] [Related]
10. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.
Kasina S; Macoska JA
Mol Cell Endocrinol; 2012 Apr; 351(2):249-63. PubMed ID: 22245379
[TBL] [Abstract][Full Text] [Related]
11. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
12. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth.
Govindarajan B; Sbrissa D; Pressprich M; Kim S; Rishi AK; Vaishampayan U; Cher ML; Chinni SR
Sci Rep; 2023 Nov; 13(1):20634. PubMed ID: 37996444
[TBL] [Abstract][Full Text] [Related]
13. Suppressing the formation of lipid raft-associated Rac1/PI3K/Akt signaling complexes by curcumin inhibits SDF-1α-induced invasion of human esophageal carcinoma cells.
Lin ML; Lu YC; Chen HY; Lee CC; Chung JG; Chen SS
Mol Carcinog; 2014 May; 53(5):360-79. PubMed ID: 23192861
[TBL] [Abstract][Full Text] [Related]
14. A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells.
Sbrissa D; Semaan L; Govindarajan B; Li Y; Caruthers NJ; Stemmer PM; Cher ML; Sethi S; Vaishampayan U; Shisheva A; Chinni SR
Oncogene; 2019 Jan; 38(3):332-344. PubMed ID: 30111818
[TBL] [Abstract][Full Text] [Related]
15. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration.
Yuan L; Zhang H; Liu J; Rubin JB; Cho YJ; Shu HK; Schniederjan M; MacDonald TJ
Mol Cancer; 2013 Mar; 12():18. PubMed ID: 23497290
[TBL] [Abstract][Full Text] [Related]
16. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
[TBL] [Abstract][Full Text] [Related]
17. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
19. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
20. CXCL12-induced partitioning of flotillin-1 with lipid rafts plays a role in CXCR4 function.
Giri B; Dixit VD; Ghosh MC; Collins GD; Khan IU; Madara K; Weeraratna AT; Taub DD
Eur J Immunol; 2007 Aug; 37(8):2104-16. PubMed ID: 17634952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]